Larvol Delta - A-Phase-2-Study-of-the-C3-Inhibitor-AMY101-in-Patients-With-ARDS-Due-to-COVID19-SAVE

AMY-101 - Amyndas

http://clinicaltrials.gov/ct2/show/NCT04395456

May 20, 2020

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next